HC Wainwright & Co. Upgrades Arcturus Therapeutics to Buy, Announces $51 Price Target

Benzinga · 05/11/2023 07:02
HC Wainwright & Co. analyst Ed Arce upgrades Arcturus Therapeutics (NASDAQ:ARCT) from Neutral to Buy and announces $51 price target.